 | Research現在、このページはご希望の言語でご利用いただけません。 Google 翻訳を使用すると自動翻訳でページを表示できます。 弊社はこのサービスの提供に責任を持たず、翻訳結果を弊社でチェックすることはありません。 For the future and in collaboration with leading pharmaceutical and biotechnology companies, Renishaw is developing implantable therapeutic delivery devices for the treatment of serious Central Nervous System (CNS) disease
Advancing precision delivery of therapeutics Renishaw is currently working with leading biotechnology and pharmaceutical companies to ensure that therapeutics that are showing great promise in the laboratory, have a means of delivery when clinical trials are performed. The complexities of taking this step have historically led to therapy programmes with great potential failing to hit designated end-points. In several key cases these failures can at least be partly attributed to an inability to consistently, precisely deliver and contain the infusate in targeted volumes. Renishaw is currently developing and testing a range of next-generation drug delivery devices that are demonstrating repeatability in infusion patterns, leading to consistency in observed therapy efficacy. In addition to offering to incorporate this development portfolio into therapeutic and academic research programmes, Renishaw offers a consultancy and associated design service to allow biotechnology and pharmaceutical companies to precisely specify delivery systems for optimal delivery of their therapeutics. For more information please use the online enquiry form, e-mail neuro@renishaw.com or call +44 (0)1453 524777 お問い合わせ詳細 や価格についてのお問い合わせは、オンラインでお寄せ下さい。直接コンタクトをご希望の場合は、 現地レニショーオフィスまでご連絡ください。 |
